Celgene Corporation (CELG), Accelerate Diagnostics Inc (AXDX) and Metabolix, Inc. (MBLX) Among Birchview’s Top Bioscience Picks
Dr. Matthew Strobeck's Birchview Capital has recently disclosed its equity holdings in a 13F filing with the SEC.
Posts Tagged ‘NASDAQ:CELG’
Biogen Idec Inc (BIIB), Celgene Corporation (CELG), bluebird bio Inc (BLUE): Stanley Druckenmiller Bets on Biotech and Wins
In the last couple of years, biotechnology industry has been a hot topic and investors have been watching closely as the industry gained on average 40% in the last three years...
Gilead Sciences, Inc., Amgen, Inc., Biogen Idec Inc Among Billionaires’ 5 Hottest Biotech Picks
With the high volatility prevalent in the biotechnology sector, investors have a hard time picking the right stocks to invest in.
Biogen Idec Inc (BIIB) and Gilead Sciences, Inc. (GILD) Two of the Three Hottest Biotech Stocks You Must Own
Biogen Idec Inc (NASDAQ:BIIB) and Gilead Sciences, Inc.
Rock Springs Capital Management’s Top 5 Largest Stock Picks
Rock Springs Capital Management is a Baltimore-based hedge fund founded in February 2013 by Kris Jenner. Prior to that, Jenner had spent 14 years working at T.
Jim Simons’ Latest Strategy is ‘Out With the New, In With the Old’
Renaissance Technologies has had one of the most successful histories of any hedge fund tracked by Insider Monkey.
Celgene Corporation (CELG), Onyx Pharmaceuticals, Inc. (ONXX): Revelations From This Blazing Biotech
With all of the heat generated by this biotech and its stock, it pays to pay attention to what Celgene Corporation (NASDAQ:CELG) says.
Celgene Corporation (CELG), Bristol-Myers Squibb Co (BMY): One Drug Dramatically Reshaping Pancreatic Cancer Treatment
A couple months may not seem like a long time, but when you're diagnosed with pancreatic cancer, the prospect of a few months makes a huge difference.
Incyte Corporation (INCY), Pfizer Inc. (PFE): This Biotech Has So Many Reasons to Be Liked
Earlier this month, I wrote an article explaining that I liked Incyte Corporation (NASDAQ:INCY) on the basis of the blockbuster potential of its only approved drug, Jakafi...
Celgene Corporation (CELG), Onyx Pharmaceuticals, Inc. (ONXX), Johnson & Johnson (JNJ): When Will the Good News End for This Biotech?
The big biotech announced on Thursday that updated results from its phase 3 study of Pomalyst in treating relapsed or refractory multiple myeloma had been published online in ...
Pharmacyclics, Inc. (PCYC), Johnson & Johnson (JNJ): The FDA Loves This Drug
It should come as no surprise to anyone that the Food and Drug Administration granted a priority review for Pharmacyclics, Inc.
Celgene Corporation (CELG), Cytokinetics, Inc. (CYTK), Astex Pharmaceuticals, Inc. (ASTX): Is the Biotech Bubble About to Burst?
"Bubble" can be a provocative word in investing circles. Think of all that comes to mind when you hear it -- perhaps other words like over-hyped, overvalued, risky, etc.
Hedge Funds Are Buying Amgen, Inc. (AMGN)
To the average investor, there are tons of metrics shareholders can use to analyze stocks. Some of the most innovative are hedge fund and insider trading activity.
Amgen, Inc. (AMGN), AstraZeneca plc (ADR) (AZN): What’s the Big Deal About Onyx Pharmaceuticals, Inc. (ONXX) Anyway?
At the end of June, Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) announced that it had rejected an offer from Amgen, Inc.
This Biogen Idec Inc. (BIIB) Data is Screaming ‘Buy, Buy, Buy’
To many market players, hedge funds are assumed to be overrated, old investment vehicles of a forgotten age.
Exelixis, Inc. (EXEL), Vertex Pharmaceuticals Incorporated (VRTX), Celgene Corporation (CELG): Want Multibaggers? Consider These 3 Biotech Companies
In after hours trading on April 18, a few hours after the release of my previous article focusing on Exelixis, Inc.
Is Celgene Corporation (CELG) Going to Burn You?
To many traders, hedge funds are perceived as overrated, outdated investment tools of a forgotten age.
Onyx Pharmaceuticals, Inc. (ONXX), Johnson & Johnson (JNJ): Celgene Corporation (CELG)’s Multiple Myeloma Powerhouse
Earlier this month, biotech powerhouse Celgene Corporation (NASDAQ:CELG) announced that the European Commission approved the combinational therapy of pomalidomide, known in the...
Pharmacyclics, Inc. (PCYC), Gilead Sciences, Inc. (GILD), Celgene Corporation (CELG): This Small Company Is Winning the War Against Blood Cancer
About 15,680 Americans are diagnosed with chronic lymphocytic leukemia, or CLL, and approximately 5,000 new cases of mantle cell lymphoma, or MCL, occur in the U.S.
Novartis AG (ADR) (NVS), Amgen, Inc. (AMGN): Incyte Corporation (INCY) Jumps on Jakafi Results
Incyte Corporation (NASDAQ:INCY) today announced positive results from a phase 2 study of its drug Jakafi in treating refractory metastatic pancreatic cancer.
Who’s Betting On Gilead Sciences, Inc. (GILD)?
If you were to ask many investors, hedge funds are seen as delayed, old financial vehicles of an era lost to time.
Visa Inc (V), Apple Inc. (AAPL): Capital Gains Today, Dividend Growth Tomorrow
One of the traits an investor should have is an ability to display forward-thinking. It is always better to see whats next instead of what has already happened.
Celgene Corporation (CELG), Compugen Ltd. (USA) (CGEN): This Week in Biotech
With the SPDR S&P Biotech Index up 40% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Agios Pharmaceuticals Inc (AGIO), Heat Biologics Inc (HTBX), Cellular Dynamics International Inc (ICEL): Are These Three Recent Biotech IPOs Worth Buying?
2013 has been a banner year for biotech IPOs.
Celgene Corporation (CELG), Novartis AG (ADR) (NVS): Momenta Pharmaceuticals, Inc. (MNTA) Earnings Remind Investors of Growing Pains
The investing waters can get pretty choppy from time to time with a developmental stage company. A look at the five-year chart of Momenta Pharmaceuticals, Inc.
3 Things You Need to Know From Astex Pharmaceuticals, Inc. (ASTX)’s Q2 Earnings
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) announced its second-quarter financial results on Thursday prior to the market open.
Alexion Pharmaceuticals, Inc. (ALXN), Celgene Corporation (CELG): Biotech Favorites With Noteworthy Drug Data
Three of the biggest names in biotechnology have reported earnings, and their quarters involved very important drug-related information for investors.
Gilead Sciences, Inc. (GILD), Celgene Corporation (CELG): Have You Considered Biotech Yet?
We are in the midst of the earnings season, my favorite time of the year.
Celgene Corporation (CELG): Has Multiple Myeloma Met its Match?
Multiple myeloma is a cancer of plasma cells, a type of white blood cell present in bone marrow.
Three Things You Need to Know From Celgene Corporation (CELG)’s Q2 Earnings
Celgene Corporation (NASDAQ:CELG) did it again. Investors have grown accustomed to the company reporting solid numbers with its earnings announcements.
Amgen, Inc. (AMGN), Celgene Corporation (CELG): Is Big Biotech Still Growing?
The first half of 2013 has seen remarkable growth in the biotech sector, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) up >40% YTD. The industry continues to...
Celgene Corporation (CELG): Does This BiotechStudy Matter to You?
Celgene Corporation (NASDAQ:CELG) fell 2.6% on Thursday after disappointing clinical data for its blood cancer drug Revlimid.
Celgene Corporation (CELG): Does This BiotechStudy Matter to You?
Celgene Corporation (NASDAQ:CELG) fell 2.6% on Thursday after disappointing clinical data for its blood cancer drug Revlimid.
Celgene Corporation (CELG): Expanding Labels to Expand Margins
In an industry where buyouts are commonplace and small-cap biotechs burn through cash rapidly, optimizing operating cash flow can be essential to a company's financial health.
Celgene Corporation (CELG): Can This Biotech Go Even Higher?
Celgene Corporation (NASDAQ:CELG) has emerged as the leading treatment provider for blood cancer.
What Does Celgene Corporation (CELG)’s Failed Trial Mean for Investors?
Early this morning, Celgene Corporation (NASDAQ:CELG) announced that it was discontinuing the phase 3 ORIGIN Trial evaluating Revlimid (lenalidomide) in B-Cell chronic lymphomatic...
Celgene Corporation (CELG), Onyx Pharmaceuticals, Inc. (ONXX): A Fundamentally Strong Biotech Stock
Celgene Corporation (NASDAQ:CELG) surged 7% on Thursday, July 11, 2013 on news that the Phase III trials of Revlimid /dexamethasone combination showed that it could be an initial...
JPMorgan Chase & Co. (JPM), Citigroup Inc (C), Celgene Corporation (CELG): A Red-Hot IPO Market Awaits These 7 New Stocks
Recent deals have performed so well that investment bankers are hustling the next crop up to the starting gate at a rapid pace. You can't blame them.
Pharmacyclics, Inc. (PCYC): Will This Be the Breakthrough of All Breakthrough Therapy Drugs?
In July 2012, the Food and Drug Administration Safety and Innovation Act was signed into law; and little did we know at the time, but the drug development process was about to...
Revlimid Results Rev Up Celgene Corporation (CELG)
Good news seems to find its way to Celgene Corporation (NASDAQ:CELG)'s door frequently these days.
Who Could Buy Onyx Pharmaceuticals, Inc. (ONXX) and at What Price?
Recently Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) rejected a $10 billion takeover offer from Amgen, Inc. (NASDAQ:AMGN).
Biogen Idec Inc. (BIIB), Celgene Corporation (CELG), Gilead Sciences, Inc. (GILD): 3 of Biotech’s Best
It’s been a healthy year-to-date for the biotech sector, with the space logging huge gains above and beyond those of the broad based market.
Amgen, Inc. (AMGN), Celgene Corporation (CELG), Biogen Idec Inc. (BIIB): Watch Out for These 3 Biotech Companies
This year, the North American players in the biotechnology industry are expected to spend $15 billion.
Amgen, Inc. (AMGN), Onyx Pharmaceuticals, Inc. (ONXX): Is This Biopharmaceutical Stock Still a Buy?
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) has recently experienced a significant jump of nearly 51.3% in only one trading day from $86.82 per share to $131.30 per share.
Starbucks Corporation (SBUX), Celgene Corporation (CELG), LinkedIn Corp (LNKD): Top 10 Performing Large Cap Stocks Through First Half of 2013
As the first half of 2013 ends, let's look at the year-to-date top performing (and profitable) large cap stocks.
Onyx Pharmaceuticals, Inc. (ONXX) Bidding Wars: Who Would Be the Best Suitor?
Recently, Amgen, Inc. (NASDAQ:AMGN) made a surprisingly low offer to acquire the pharmaceutical company Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX).
Onyx Pharmaceuticals, Inc. (ONXX) Says the Price Isn’t Right
That's the message from Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) over the weekend after Amgen, Inc. (NASDAQ:AMGN) made an unsolicited offer to buy the company.
Ariad Pharmaceuticals, Inc. (ARIA), VIVUS, Inc. (VVUS): Winning Biotech Investment Strategies and Their Potential Pitfalls
Investing in biotech companies isn't without its challenges, but it doesn't have to be a shot in the dark, either.
Oncolytics Biotech, Inc. (USA) (ONCY): This High-Risk, High-Reward Biotech Is Worth a Look
Let me preface this by saying that investing in the biotech sector can sometimes be nothing more than speculating.
